Blog

For years, the life sciences industry has invested heavily in finding patients earlier, more accurately, and at greater scale. As data sources expand and machine learning models improve, patient-finding programs have become more sophisticated. A new generation of AI capabilities now...

China's reimbursement environment changed with the introduction of the NRDL value rating framework in 2023 and the Commercial Insurance Innovative Drug List (CIIDL) in 2025. NRDL 2025 outcomes show that payers continue rewarding breakthrough therapies, comparative evidence, and treatments for unmet...

Primary market research (PMR) has long been a trusted advisor to brand teams, helping organizations understand customers, test assumptions, and reduce uncertainty in critical business decisions. Over the past decade, however, many PMR organizations have been asked to do more with...

Oncology markets are no longer defined only by tumor type or line of therapy. AI, patient-level data, and primary research now help teams define markets by biology, care pathways, and access barriers. That shift can shape development strategy, trial design, and...

Direct-to-patient (DTP) channels have quietly moved from the margins of pharma to a central lever in high-demand categories. One-third of new Zepbound prescriptions in the U.S. are now being filled through LillyDirect, bypassing insurers, PBMs, and traditional pharmacy channels entirely. A...

Scott Evangelista Chief Executive Officer When I sat down with Jane King on New to the Street, I had one message I wanted every viewer to walk away with. Trinity is the leader integrating human and artificial intelligence in commercialization. Life...